Practical Information

Registration opening 17 May 2018

KEY DATES
Registration opening 17 May 2018
Early Registration 17 May - 16 August 2018
Late Registration 16 August - 15 November 2018

VENUE
Radisson Blu Royal Hotel, Brussels
Rue Fossé-aux-loups
1000 Brussels, Belgium
Dear Colleagues,

We are honoured to introduce you to the IBCD 2018: **Innovation and Biomarkers in Cancer Drug Development** conference. This is a unique joint meeting organized by the European Organisation for Research and Treatment of Cancer (EORTC), an academic research organization, the US National Cancer Institute (NCI), a governmental institution, the European Medicines Agency (EMA), a regulatory agency, and the American Association for Cancer Research (AACR), a professional scientific association.

In recent years, cancer drug and biomarker development and implementation in daily practice has become so complex that it requires a diverse range of expertise. The intention of IBCD 2018 is to shine a spotlight on multi-stakeholder approaches to cancer drug development with new cancer biomarkers in a scientific programme which includes input from regulators, industry, academia, patients and payers.

IBCD 2018 will explore routes through the constantly evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA and Health Technology Assessment specialists endeavour to build upon the recommendations and action points decided upon at the IBCD2016-edition. Topics, such as, Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice will be addressed. The conference will also discuss the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.

We welcome your support for this meeting which will foster new forms of partnerships between academia, industry, regulatory, health technology assessment bodies and payers adding value to tomorrow’s personalized cancer treatments for patients in a daily practice setting.

Denis Lacombe and Roberto Salgado, Co-chairs
IBCD IN A NUTSHELL

IBCD welcomed 178 participants in 2016.

Delegates status

- Academic
- Biotech/Technology/Diagnostic
- Media
- European Bodies
- Foundation
- Governmental Institutions
- Industry
- Patient/Patient advocacy
- Regulators

Delegates participation by continent

- Oceania
- Europe
- Asia
- North America
GRANTS

The provision of Education Grants help to provide the most appropriate setting for participants to learn about the evolving scientific, methodological and regulatory environment for drug and biomarker development. The grants support the meeting facilities and operational activities, helping to provide the most appropriate setting for participants to establish new approaches translating clinical trial data into daily practice, as well as networking and holding discussions with their peers, etc. This is a major aid and advancement to the quality and impact of the scientific programme.

Your support will be acknowledged on the conference website and in the programme book.

SPONSORING

Increase your brand recognition promoting your company to a targeted audience and become an IBCD partner!

Partner Support Package

Major Sponsor (20 000 Euros)
Acknowledgment on the conference website and in the promotional material
Three complimentary registrations for the meeting

Sponsor (15 000 Euros)
Acknowledgment on the conference website and in the promotional material
Two complimentary registrations for the meeting

Contributor (10 000 Euros)
Acknowledgment on the conference website and in the promotional material
One complimentary registration for the meeting

Supporter (5 000 Euros)
Acknowledgment on the conference website and in the promotional material
SPONSORSHIP OPPORTUNITIES

Networking

- Coffee Breaks 6 000 euros
- Lunch Break 10 000 euros

Breaks will allow delegates to talk to each other. Breaks will be the perfect moment to present the activities of your company. A roll up branded will be placed in the networking room.

Advertisement

- Lanyards 1 000 euros

Be the sponsor and guarantee your visibility during the whole congress (logo placed on the lanyard). Limited to 1 sponsor.

- Pens and Notepads 1 000 euros

Advertising opportunity ensuring visibility for your company. Limited to 1 sponsor. Costs production are not included.

Educational

- Webcasts 9 000 euros

Webcasts will be available on the conference website after the event. The company will be acknowledged on the webcasts web page.
PRELIMINARY PROGRAMME

THURSDAY

29/11

SETTING THE SCENE

SESSION 1
Evidence driven healthcare systems: the way forward

09:00 AM - 09:30 AM  Speakers: D. Lacombe & R. Salgado

09:30 AM - 09:50 AM  Current scenario for diagnostics including molecular and immunological screening
                      Speaker: to be confirmed

09:50 AM - 10:10 AM  Compassionate use and Pre-approval access
                      Speaker: to be confirmed

10:10 AM - 10:30 AM  The impact of drug access upon survival in Europe
                      Speaker: to be confirmed

10:30 AM - 10:50 AM  HTA perspective
                      Speaker: to be confirmed

Coffee break

10:50 AM - 11:15 AM

PANEL DISCUSSION

11:15 AM - 12:30 PM  Panelists: to be confirmed

Lunch break

12:30 PM - 13:30 PM
SESSION 2
Challenges of Clinical Trial Design: New Perspectives

13:30 PM - 13:45 PM  NCI MATCH trial: Lessons learnt
Speaker: to be confirmed

13:45 PM - 14:00 PM  Japanese precision medicine trials: the way forward
Speaker: to be confirmed

14:00 PM - 14:15 PM  EORTC SPECTA: Challenges of a European platform for precision medicine
Speaker: to be confirmed

14:15 PM - 14:30 PM  Regulatory issues on molecular testing
Speaker: to be confirmed

14:30 PM - 14:45 PM  Are companion diagnostic useful?
Speaker: to be confirmed

Coffee break
14:45 PM - 15:15 PM

PANEL DISCUSSION
15:15 PM - 16:30 PM  Panelists: to be confirmed
SESSION 3
Generating the scientific evidence: the challenges in implementing to daily practice

09:30 AM - 09:45 AM  Liquid biopsy: Validation of cell free DNA profiling
Speaker: to be confirmed

09:45 AM - 10:00 AM  Germline testing to dictate drug response
Speaker: to be confirmed

10:00 AM - 10:15 AM  Centralized testing vs local testing from the industry perspective
Speaker: to be confirmed

10:15 AM - 10:30 AM  Centralized testing vs local testing from the academic perspective
Speaker: to be confirmed

10:30 AM - 10:45 AM  Data sharing: How can we leverage big data?
Speaker: to be confirmed

Coffee break  10:45 AM - 11:15 AM

PANEL DISCUSSION  11:15 AM - 12:30 PM  Panelists: to be confirmed

CLOSING REMARKS  12:30 PM - 13:00 PM  Speakers: D. Lacombe & R. Salgado

For more information about the programme, please go to the IBCD website
For further information, please contact:
IBCD Secretariat
EORTC
Avenue E. Mounier 83
1200 Brussels, Belgium
www.eortc.org/ibcd • events@eortc.org